Histology
Transitional Cell Carcinoma
CI-CAN-00001613Explore in graph →
254 active trials5 approved drugs22 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001613Explore in graph →
Clinical trials
735 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (119)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05912205 | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT02450331 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection(IMvigor010) | terminated | Phase 3 | 809 | Hoffmann-La RocheINDUSTRY |
| 24 |
| Jun 18, 2023 |
| clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | terminated | Phase 2 | 97 | pharmaand GmbHINDUSTRY | 6 | Jun 9, 2023 | clinicaltrials |
| NCT05895864 | Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05893316 | UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study | unknown | — | 1,000 | Changhai HospitalOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04617756 | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract(iNDUCT) | recruiting | Phase 2 | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT04314245 | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma | completed | — | 1,170 | AnchorDx Medical Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03359239 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | completed | Phase 1 | 10 | Matthew GalskyOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT05833997 | Safety Analysis and Oncological Outcomes in HoLERT vs TURBT | unknown | N/A | 100 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05107427 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma(AVENU) | withdrawn | Phase 2 | 0 | 4D pharma plcINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 14, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | unknown | Phase 2 | 80 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03330886 | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | completed | — | 13 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03854721 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | completed | Phase 1 | 6 | Vaxiion TherapeuticsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | terminated | Phase 1 | 13 | Advaxis, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05723991 | Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma | unknown | Phase 4 | 36 | Chunguang yang (101937)OTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02581982 | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | completed | Phase 2 | 27 | Wake Forest University Health SciencesOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | terminated | — | 2 | xCuresINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03464734 | Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | completed | Phase 2 | 70 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04730219 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | unknown | Phase 2 | 48 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT00805129 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03584659 | Patient-reported Outcomes in Bladder Cancer(iBLAD) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01688999 | Cabozantinib for Advanced Urothelial Cancer | completed | Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02437370 | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | completed | Phase 1 | 32 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT00070070 | Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas | completed | Phase 1 | 6 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | completed | Phase 2 | 108 | Matthew GalskyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT04077359 | Prospective Trial for Examining Hematuria Using Computed Tomography(PROTEHCT) | completed | N/A | 300 | Oslo University HospitalOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT03232593 | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | completed | — | 1,758 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2023source: clinicaltrials